## Clinical Diagnosis **Key Point:** The clinical presentation — COPD, ICU admission, bilateral infiltrates, purulent sputum, oxidase-positive Gram-negative rods with fruity odor — is pathognomonic for *Pseudomonas aeruginosa* ventilator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP). ## Antibiotic Selection for *P. aeruginosa* | Feature | Consideration | |---------|---------------| | **Organism** | *Pseudomonas aeruginosa* — intrinsically resistant to many β-lactams | | **Empiric coverage needed** | Anti-pseudomonal β-lactam (piperacillin-tazobactam or cefepime) ± aminoglycoside | | **Monotherapy adequacy** | Piperacillin-tazobactam or cefepime alone is acceptable for HAP/VAP in most guidelines | | **Fluoroquinolone role** | NOT recommended as monotherapy for severe *P. aeruginosa* infection; reserve for oral step-down or mild community-acquired infections | ## Recommended Regimen **High-Yield:** For HAP/VAP with suspected or confirmed *P. aeruginosa*: - **First-line:** Piperacillin-tazobactam 4.5 g IV 6-hourly OR Cefepime 2 g IV 8-hourly - **Addition of aminoglycoside** (e.g., amikacin 15 mg/kg IV daily) is optional in non-severe cases but often added in ICU/severe VAP for synergy and rapid source control **Clinical Pearl:** *P. aeruginosa* is an opportunistic pathogen in ICU/ventilated patients. Early, adequate anti-pseudomonal coverage reduces mortality. Monotherapy with a β-lactam is acceptable; dual therapy (β-lactam + aminoglycoside) is reserved for severe sepsis or immunocompromised hosts. **Warning:** Ceftriaxone and amoxicillin-clavulanate have poor anti-pseudomonal activity and should NOT be used. Fluoroquinolone monotherapy is inadequate for severe *P. aeruginosa* pneumonia. [cite:Harrison 21e Ch 157] [cite:KD Tripathi 8e Ch 58]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.